



Rozerem[®] (ramelteon) – First-time generic

- On July 23, 2019, [Teva](#) and [Dr. Reddy's](#) launched [AB-rated](#) generic versions of Takeda's [Rozerem \(ramelteon\)](#) tablets.
 - Zydus received FDA approval of an [AB-rated](#) generic version of Rozerem on July 22, 2019. Launch information for this generic is pending.
- Rozerem is approved for the treatment of insomnia characterized by difficulty with sleep onset.
- According to IQVIA Health, Rozerem had U.S. sales of approximately \$91 million for the most recent twelve months ending in May 2019.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.